KC biotech developing KU cancer drug clears big FDA hurdle

A Kansas City biotech company moved one large step closer to FDA approval for its cancer drug. CicloMed LLC gained Food and Drug Administration approval to begin human clinical trials for bladder cancer patients, the company announced Wednesday. About 79,000 new cases of bladder cancer will be diagnosed this year, according to the American Cancer Society. The treatment not only is an advan cement for bladder cancer patients, but it also is the first drug developed at The University of Kansas Cancer…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news